• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email
    SC 13G/A 1 lenz1015247sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Lenz Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

     

    52635N103

    (CUSIP Number)

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 8 Pages 
     

     

    CUSIP No. 52635N103

     

    13G/A Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    766,940

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    766,940

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    766,940

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    2.8%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    Lenz Therapeutics, Inc., a Delaware corporation, formerly known as Graphite Bio, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA 92075

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management; and Tang Capital Partners, LP (“Tang Capital Partners”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP Number 52635N103

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 766,940 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 27,496,665 shares of Common Stock outstanding as of August 9, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 14, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 2.8%
    Kevin Tang 2.8%
    Tang Capital Partners 2.8%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 766,940 shares
    Kevin Tang 766,940 shares
    Tang Capital Partners 766,940 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 766,940 shares
    Kevin Tang 766,940 shares
    Tang Capital Partners 766,940 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     Page 6 of 8 Pages 
     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $LENZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    3/27/2024$28.00Overweight
    Piper Sandler
    More analyst ratings

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Versant Venture Capital Vi, L.P. sold $10,255,244 worth of shares (260,713 units at $39.34) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    8/19/25 4:51:33 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $6,506,784 worth of shares (191,376 units at $34.00) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    7/14/25 4:50:19 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $6,093,000 worth of shares (200,000 units at $30.46) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    7/1/25 6:16:12 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by LENZ Therapeutics Inc.

    SCHEDULE 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    8/20/25 5:13:51 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

    7/31/25 4:55:14 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by LENZ Therapeutics Inc.

    10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

    7/30/25 4:03:37 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/15/24 4:13:06 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

    VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT  SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based

    7/31/25 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercialization agreements for LNZ100 including over $195 million in upfront and milestone payments together with double-digit royalties on net sales Cash, cash equivalents and marketable securities of $209.6 million as of June 30, 2025 SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the develop

    7/30/25 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

    SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that CORXEL Pharmaceuticals ("CORXEL") has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC). LENZ licensed the Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022. The NDA submission was

    7/28/25 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

    Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

    4/14/25 8:17:08 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on LENZ Therapeutics with a new price target

    TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

    3/18/25 7:53:26 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on LENZ Therapeutics with a new price target

    Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00

    9/27/24 7:38:17 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lucy Therapeutics Appoints Kim Drapkin as Board Chair

    Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

    10/15/24 8:00:00 AM ET
    $ABOS
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

    Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

    6/10/24 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Financials

    Live finance-specific insights

    View All

    LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

    VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT  SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based

    7/31/25 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

    New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

    5/7/25 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

    SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inve

    4/30/25 4:30:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

    SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/8/24 5:08:56 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by LENZ Therapeutics Inc.

    SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

    7/29/24 4:12:50 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care